RGNX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

10.770

Open

10.350

VWAP

10.18

Vol

1.11M

Mkt Cap

510.97M

Low

9.870

Amount

11.33M

EV/EBITDA(TTM)

--

Total Shares

51.61M

EV

467.92M

EV/OCF(TTM)

--

P/S(TTM)

3.00

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

Show More

Events Timeline

(ET)

2026-03-08

22:30:00

KKR Plans to Sell CoolIT Systems for Over $3B

2026-03-08

17:00:00

Dr. Vinay Prasad to Leave Agency at End of April

2026-03-05 (ET)

2026-03-05

07:10:00

Regenxbio Reports Q4 Revenue of $30.3M

2026-03-03 (ET)

2026-03-03

07:50:00

FDA Tightens Accelerated Approval Pathway, Rejects Regenxbio and Disc Medicine

2026-02-26 (ET)

2026-02-26

11:10:00

Leerink: uniQure Stock Drops 25%

2026-02-20 (ET)

2026-02-20

11:50:00

Court Revives Regenxbio, UPenn Patent Suit Against Sarepta

News

Globenewswire

03-10Globenewswire

Regenxbio Faces Class Action Lawsuit Reminder

Globenewswire

03-09Globenewswire

REGENXBIO Faces Class Action Lawsuit Over Securities Violations

Benzinga

FDA CBER Head Dr. Vinay Prasad to Depart, Impact on Moderna and Rare Disease Stocks

Globenewswire

03-09Globenewswire

REGENXBIO Investors Class Action Notice Issued

Benzinga

Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data

seekingalpha

03-09seekingalpha

Biotech Stocks Surge Following FDA Vaccine Chief's Departure

7 Analyst Rating

Wall Street analysts forecast RGNX stock price to rise

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

19.00

Averages

29.71

High

45.00

Current: 0.000

Low

19.00

Averages

29.71

High

45.00

H.C. Wainwright

Buy

downgrade

$32 -> $30

AI Analysis

2026-03-09

New

Reason

H.C. Wainwright

Price Target

$32 -> $30

AI Analysis

2026-03-09

New

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Regenxbio to $30 from $32 and keeps a Buy rating on the shares following the Q4 report.

Stifel

Buy

downgrade

$45 -> $42

2026-03-05

Reason

Stifel

Price Target

$45 -> $42

2026-03-05

downgrade

Buy

Reason

Stifel lowered the firm's price target on Regenxbio to $42 from $45 and keeps a Buy rating on the shares. The firm notes the company is moving toward pivotal readouts for RGX-202/ Duchenne muscular dystrophy and ABBV-RGX-314/ wet age related macular degeneration, with among the most comprehensive and/or largest datasets in GTx. Ahead of the 202 readout, Stifel expects additional color at the Muscular Dystrophy Association next week for further insight into safety and durability of functional benefit, offering a window into AFFINITY-DUCHENNE.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RGNX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Regenxbio Inc (RGNX.O) is -4.94, compared to its 5-year average forward P/E of 1.84. For a more detailed relative valuation and DCF analysis to assess Regenxbio Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

1.84

Current PE

-4.94

Overvalued PE

22.02

Undervalued PE

-18.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-1.34

Current EV/EBITDA

73.60

Overvalued EV/EBITDA

13.75

Undervalued EV/EBITDA

-16.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

5.85

Current PS

2.89

Overvalued PS

9.34

Undervalued PS

2.36

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

news about stocks that are below 10 dollar

Intellectia · 100 candidates

Region: USPrice: $1.00 - $10.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000News Driver: Positive, Negative

Ticker

Name

Market Cap$

XWELL Inc

6.98M

Larimar Therapeutics Inc

494.39M

VS Media Holdings Ltd

5.06M

Evolent Health Inc

350.52M

Navitas Semiconductor Corp

2.27B

Sharplink Inc

1.46B

update list for stock prices between 5-50

Intellectia · 64 candidates

Price: $5.00 - $50.00Moving Average Relationship: PriceBelowMA20Week Price Change Pct: <= $-7.00Month Price Change Pct: <= $-10.00Monthly Average Dollar Volume: >= 800,000

Ticker

Name

Market Cap$

Venu Holding Corp

364.84M

Regenxbio Inc

698.09M

Anbio Biotechnology

2.89B

SMX (Security Matters) PLC

156.97M

Northrim BanCorp Inc

510.78M

Array Digital Infrastructure Inc

4.03B

stocks bearish for a week

Intellectia · 82 candidates

Price: >= $5.00Moving Average Relationship: PriceBelowMA20Week Price Change Pct: <= $-7.00Month Price Change Pct: <= $-10.00Monthly Average Dollar Volume: >= 800,000

Ticker

Name

Market Cap$

Venu Holding Corp

364.84M

Regenxbio Inc

698.09M

Anbio Biotechnology

2.89B

Humana Inc

25.28B

Commvault Systems Inc

4.05B

SMX (Security Matters) PLC

156.97M

Whales Holding RGNX

Integral Health Asset Management, LLC

Voss Capital, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Regenxbio Inc (RGNX) stock price today?

The current price of RGNX is 9.9 USD — it has decreased -4.62

What is Regenxbio Inc (RGNX)'s business?

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

What is the price predicton of RGNX Stock?

Wall Street analysts forecast RGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGNX is29.71 USD with a low forecast of 19.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Regenxbio Inc (RGNX)'s revenue for the last quarter?

Regenxbio Inc revenue for the last quarter amounts to 30.34M USD, increased 43.00

What is Regenxbio Inc (RGNX)'s earnings per share (EPS) for the last quarter?

Regenxbio Inc. EPS for the last quarter amounts to -1.30 USD, increased 28.71

How many employees does Regenxbio Inc (RGNX). have?

Regenxbio Inc (RGNX) has 371 emplpoyees as of March 11 2026.

What is Regenxbio Inc (RGNX) market cap?

Today RGNX has the market capitalization of 510.97M USD.